9
4
5
↑9
↓4
—5
Evidence suggests Melatonin mayincreaseMood.
28 studies (18 claims)
Emerging evidence
Typical effective dose 6 (4.25–18.5) mgacross 7 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| melatonin analogues | Increases - antidepressant and normalizing circadian rhythm actions | mood and circadian rhythm | Human | glaucoma patients | Not specified | Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.cited 21× |
| melatonin | No effect - effects | management of mood disturbances | HumanMolecular | cancer patients | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | No effect - influence | mood | HumanMolecular | — | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| melatonin | No effect - evidence is accumulating on a possible role for influencing | mood | Human | — | Not specified | Melatonin as a treatment for mood disorders: a systematic review.cited 36× |
| melatonin | No effect - determine the efficacy and acceptability of | mood disorders | Human | patients with mood disorders | Not specified | Melatonin as a treatment for mood disorders: a systematic review.cited 36× |
| melatonin | No effect - There is no evidence for an effect of on | mood disorders | Human | — | Not specified | Melatonin as a treatment for mood disorders: a systematic review.cited 36× |
| melatonin | No effect - evidence for an effect of in improving is not significant | mood symptoms | Human | patients with depressive episodes | Not specified | Melatonin as a treatment for mood disorders: a systematic review.cited 36× |
| melatonin | No effect - effect on | mood | Human | individuals with MCI | 25 mg oral melatonin nightly. | Feasibility of 3-month melatonin supplementation for brain oxidative stress and sleep in mild cognitive impairment: protocol for a randomised, placebo-controlled study.cited 7× |
| melatonin | Increases - demonstrated a significant improvement | mood | HumanAnimal | women receiving melatonin vs placebo | — | Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis. |
| melatonin | Increases - improved | mood | Human | human participants | — | Differential Function of Melatonin MT |
| melatonin | No effect - regulates | mood | Human | humans | — | No title available |
| melatonin | Increases - there was a trend towards an improvement | mood | Human | participants with a Diagnostic and Statistical Manual of Mental Disorders (fourth edition) diagnosis of MDD and early-morning waking | 6 mg slow-release melatonin at bedtime. | A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.cited 48× |
| melatonin | No effect - is essential for the control of | mood and behavior | Human | — | Not specified | Role of melatonin in mood disorders and the antidepressant effects of agomelatine. |
| melatonin | No effect - is essential for the control of | mood and behavior | Human | — | Not specified | Role of melatonin in mood disorders and the antidepressant effects of agomelatine. |
| Melatonin | No effect - alterations in synthesis and secretion | mood disorders | Human | patients with major depressive disorder | — | Role of the MT |
| melatonin | No effect - reviewed, with a focus on their use for treating | mood disorders | Human | children and adolescents | Not specified | Mood Disorders in Youth: Complementary and Integrative Medicine.cited 2× |
| melatonin | Decreases - could be used as an adjuvant treatment | mood disorders | Human | patients during acute phases | 0.125mg (small dose mentioned for chronobiotic action; dose-effect relationship noted for sleep-inducing effects). | The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS).cited 35× |
| melatonin | No effect - no significant improvements | mood disorders | Human | breast cancer patients undergoing hormone therapy | 6 mg daily | Melatonin Aids in Treating Mood and Sleep Problems Resulting from Hormonal Therapy in Breast Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. |
| melatonin | No effect - did not find substantial evidence supporting the use | mood disorders | Human | breast cancer patients | 6 mg daily | Melatonin Aids in Treating Mood and Sleep Problems Resulting from Hormonal Therapy in Breast Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. |
| Melatonin | No effect - plays an important physiologic role | regulation of mood | Human | — | Not specified | Melatonin in septic shock: some recent concepts.cited 64× |
| melatonin | No effect - influences | sleep and mood | Human | — | Not specified | Exploring the association between melatonin and nicotine dependence (Review).cited 1× |
| melatonin | Decreases - attenuates | sleep disturbance, mood changes, and cognitive impairment | Human | — | — | Melatonin for premenstrual syndrome: A potential remedy but not ready.cited 5× |
| exogenous melatonin | Increases - reported as serious or of clinical significance | agitation, fatigue, mood swings, nightmares, skin irritation and palpitations | Human | subjects with sleep disorders | Daily doses ranged from 0.15 mg to 12 mg. | Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.cited 93× |
| pharmacologic treatments with modafinil and melatonin | Increases - suggest potential treatments including | alertness, vigilance, and mood | Human | Individuals with TBI | Not specified | Fatigue and sleep disturbance following traumatic brain injury--their nature, causes, and potential treatments.cited 148× |
| 25 mg oral melatonin nightly | No effect - no significant differences | mood | Human | Participants with Mild Cognitive Impairment (MCI) | 25 mg nightly | 3-Month Melatonin Supplementation to Reduce Brain Oxidative Stress and Improve Sleep in Mild Cognitive Impairment: A Randomised Controlled Feasibility Trial.cited 1× |
| long-term oral melatonin administration | Increases - had beneficial effects on | mood | Human | patients with advanced glaucoma | Daily at 10:30 pm (specific dosage amount not provided). | Melatonin mitigates disrupted circadian rhythms, lowers intraocular pressure, and improves retinal ganglion cells function in glaucoma.cited 38× |
| Pediatric-appropriate prolonged-release melatonin (Ped-PRM) | Increases - demonstrate | mood swings | Human | — | — | Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder.cited 6× |
| natural compound, composed of melatonin (1,5 mg) and cannabis extracts (2.5 mg CBD) | Decreases - evidenced reduction | mood alterations, including anxiety, panic, paranoia, depression | Human | patients with sleep disorders | 1.5 mg melatonin and 2.5 mg CBD (20 drops sublingually overnight). | Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts.cited 3× |